You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 20, 2025

CLINICAL TRIALS PROFILE FOR DRONEDARONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Dronedarone Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00174785 ↗ A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation Completed Sanofi Phase 3 2005-06-01 To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL). To assess that dronedarone is well tolerated in this population.
NCT00259376 ↗ American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm Completed Sanofi Phase 3 2001-11-01 To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL). To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence. To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.
NCT00259428 ↗ EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS) Completed Sanofi Phase 3 2001-11-01 To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL). To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms. To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence.
NCT00489736 ↗ Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation Completed Sanofi Phase 3 2007-06-01 The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.
NCT00696631 ↗ European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure Terminated Sanofi Phase 3 2002-06-01 The purpose of this study is to assess the efficacy, tolerability and safety of dronedarone versus placebo in patients with symptomatic congestive heart failure (CHF) and left ventricular dysfunction (LVD) when added to evidence based treatments for CHF.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dronedarone Hydrochloride

Condition Name

Condition Name for Dronedarone Hydrochloride
Intervention Trials
Atrial Fibrillation 25
Atrial Flutter 3
Stevens-Johnson Syndrome 1
Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dronedarone Hydrochloride
Intervention Trials
Atrial Fibrillation 28
Recurrence 4
Atrial Flutter 3
Severe Acute Respiratory Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dronedarone Hydrochloride

Trials by Country

Trials by Country for Dronedarone Hydrochloride
Location Trials
United States 89
Poland 16
Germany 10
Netherlands 10
United Kingdom 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dronedarone Hydrochloride
Location Trials
New Jersey 5
New York 5
Texas 4
California 4
Wisconsin 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dronedarone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dronedarone Hydrochloride
Clinical Trial Phase Trials
Phase 4 12
Phase 3 10
Phase 2/Phase 3 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dronedarone Hydrochloride
Clinical Trial Phase Trials
Completed 15
Terminated 5
Unknown status 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dronedarone Hydrochloride

Sponsor Name

Sponsor Name for Dronedarone Hydrochloride
Sponsor Trials
Sanofi 17
Eastbourne General Hospital 2
Vanderbilt University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dronedarone Hydrochloride
Sponsor Trials
Other 31
Industry 21
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Dronedarone Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction

Dronedarone hydrochloride, marketed under the brand name Multaq, is an antiarrhythmic drug used primarily for the management of atrial fibrillation (AF) and atrial flutter. Here, we will delve into the clinical trials, market analysis, and projections for this drug.

Clinical Trials

DAFNE Study

The Dronedarone Atrial Fibrillation Study After Electrical Cardioversion (DAFNE) was one of the first clinical trials to evaluate dronedarone. This study involved patients with persistent AF who were successfully cardioverted and then randomized to receive dronedarone at various doses or a placebo. The results showed that dronedarone significantly reduced the recurrence of AF and increased the time to AF relapse compared to the placebo group[1].

ANDROMEDA Trial

The Antiarrhythmic Trial with Dronedarone in Moderate-to-Severe Congestive Heart Failure Evaluating Morbidity Decrease (ANDROMEDA) trial was designed to assess whether dronedarone could reduce the occurrence of death or hospitalization for heart failure in patients with symptomatic heart failure. However, this trial was terminated early due to increased mortality in the dronedarone group, indicating that dronedarone is not safe for patients with moderate-to-severe heart failure[1].

PALLAS Trial

The Permanent Atrial FibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS) trial evaluated the effectiveness of dronedarone in patients with permanent AF. This trial was also terminated early due to a significantly higher number of cardiovascular events, including deaths, strokes, and hospitalizations for heart failure, in the dronedarone-treated group compared to the placebo group[3].

ATHENA Trial

The ATHENA trial, which supported the approval of dronedarone for non-permanent AF, showed a reduction in the risk of hospitalizations for AF without an increased risk of cardiovascular death, stroke, or heart failure. This trial highlighted the benefit of dronedarone for patients with non-permanent AF[3].

Pharmacology and Metabolism

Dronedarone is a noniodinated benzofuran derivative of amiodarone, lacking the iodine moiety which reduces the risk of thyroid and pulmonary toxicity. It is metabolized via the cytochrome P450 3A4 isoenzyme system, with its metabolites excreted mainly in the feces. Only a small percentage of dronedarone is eliminated renally, making it less influenced by changes in renal function[1].

Drug Interactions and Safety Concerns

Dronedarone can interact with other drugs undergoing tubular excretion, such as amantadine, metformin, and procainamide. It also affects the renal handling of creatinine, leading to elevated serum creatinine levels, although this effect is reversible and does not indicate impaired renal function[1].

The FDA has issued safety updates highlighting the increased risk of serious cardiovascular events, including death, when dronedarone is used in patients with permanent AF. However, for patients with non-permanent AF, the benefits of dronedarone are considered to outweigh the risks when used appropriately[3].

Market Analysis

Global Market Insights

The global dronedarone hydrochloride market is analyzed based on market size, trends, and demand forecasts. The market is segmented by type, application, company, and region. Key factors affecting the market include the increasing prevalence of atrial fibrillation, advancements in healthcare infrastructure, and the competitive landscape among pharmaceutical companies[5].

Market Size and Forecast

The market size for dronedarone hydrochloride is expected to grow over the forecast period from 2025 to 2031, driven by the rising incidence of AF and the need for effective antiarrhythmic treatments. The market report provides detailed forecasts, including CAGR and revenue share, as well as regional and country-level analyses[2][5].

Regional Analysis

The global market is dominated by regions with advanced healthcare systems and high prevalence rates of AF. North America and Europe are expected to be significant markets, while Asia-Pacific is anticipated to show rapid growth due to increasing healthcare expenditure and a growing patient population[5].

Competitive Landscape

The market for dronedarone hydrochloride is competitive, with several pharmaceutical companies involved in its production and distribution. The competitive landscape includes key company profiles, market trends, and strategic analyses such as SWOT and PESTEL analyses[2].

Projections and Future Outlook

Growth Drivers

The growth of the dronedarone hydrochloride market is driven by several factors, including the increasing prevalence of atrial fibrillation, aging populations, and advancements in healthcare technologies. Additionally, the need for effective and safe antiarrhythmic treatments continues to drive demand for dronedarone[5].

Challenges and Restraints

Despite the growth potential, the market faces challenges such as safety concerns, particularly in patients with permanent AF or severe heart failure. Regulatory scrutiny and the risk of adverse cardiovascular events are significant restraints that need to be addressed through careful patient selection and monitoring[3].

Technological Trends

Advancements in drug delivery systems and ongoing research into new indications for dronedarone are expected to influence the market positively. The integration of digital health technologies for better patient monitoring and adherence could also enhance the market outlook[2].

Key Takeaways

  • Clinical Trials: Dronedarone has shown efficacy in reducing AF recurrence in non-permanent AF but is not recommended for patients with permanent AF or severe heart failure due to increased cardiovascular risks.
  • Pharmacology: Dronedarone is metabolized via the CYP3A4 isoenzyme system and has a reversible effect on serum creatinine levels.
  • Market Analysis: The global market for dronedarone hydrochloride is expected to grow, driven by the increasing prevalence of AF and advancements in healthcare.
  • Projections: The market will be influenced by growth drivers such as aging populations and technological advancements, but also faces challenges related to safety concerns and regulatory scrutiny.

FAQs

What is dronedarone hydrochloride used for?

Dronedarone hydrochloride is used for the management of atrial fibrillation (AF) and atrial flutter, particularly in patients with non-permanent AF.

What are the key clinical trials for dronedarone?

Key clinical trials include the DAFNE, ANDROMEDA, PALLAS, and ATHENA trials, which have evaluated the efficacy and safety of dronedarone in different patient populations.

What are the safety concerns associated with dronedarone?

Dronedarone is associated with increased risks of serious cardiovascular events, including death, in patients with permanent AF or severe heart failure. It also affects serum creatinine levels, although this effect is reversible.

What is the market outlook for dronedarone hydrochloride?

The market is expected to grow due to the increasing prevalence of AF and advancements in healthcare technologies, despite facing challenges related to safety concerns and regulatory scrutiny.

Which regions dominate the global dronedarone hydrochloride market?

North America and Europe are significant markets, while the Asia-Pacific region is expected to show rapid growth due to increasing healthcare expenditure and a growing patient population.

References

  1. Managed Healthcare Executive: "Dronedarone: An antiarrhythmic agent for the management of atrial fibrillation and atrial flutter"[1].
  2. Cognitive Market Research: "Global Dronedarone Hydrochloride Tablets Market Report 2024 Edition"[2].
  3. FDA: "Review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular events"[3].
  4. Patsnap: "Dronedarone Hydrochloride - Drug Targets, Indications, Patents"[4].
  5. QYResearch: "Global Dronedarone Hydrochloride Market Insights, Forecast to 2029"[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.